Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q3 2017 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Nov 2, 2017

  1. Slide 1: Third Quarter 2017 Results

    NewLink Genetics Corporation Nasdaq: NLNK November 2, 2017 Third Quarter 2017 Results

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments & Outlook  Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates & Guidance on Timing of Data  Eugene P. Kennedy, M.D., Vice President Clinical & Medical Affairs Third Quarter 2017 Fin

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w

  4. Slide 4: Recent Highlights

    Recent Highlights  Progression toward Pivotal trial in advanced melanoma achieved with parameters of trial design established and reviewed by FDA  Updated Phase 2 data for indoximod plus PD-1 checkpoint inhibitor KEYTRUDA® suggest substantial improvement of response rate for advanced melanoma pati

  5. Slide 5: Best Response by Patient with Advanced Melanoma

    Best Response by Patient with Advanced Melanoma 5 Significant Depth of Response *Patients that progressed due to new non-target lesions. Note: 1 patient was unevaluable for response due to pleural effusion/collapsed left lung; the patient progressed based on several new non-target lesions. Zakharia

  6. Slide 6: Indoximod Pivotal Phase Study Design

    Indoximod Pivotal Phase 3 Study Design Two-Arm, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study  Randomization via an interactive web system  Stratified by: ̶ Checkpoint inhibitor (pembro or nivo) ̶ Prior BRAF treatment ̶ Advanced stage disease at randomization  Investigator choice

  7. Slide 7: Clinical Collaboration between AstraZeneca and NewLink

    Clinical Collaboration between AstraZeneca and NewLink Phase 2 Randomized, Placebo Controlled Trial of IDO plus anti-PDL-1  Statistically powered to compare 4 drug regimen to Standard of Care (SOC)  Primary Endpoint: Overall Response  Secondary Endpoints: ̶ Overall Survival ̶ Progression Free Sur

  8. Slide 8: Third Quarter 2017 Financial Results

    Third Quarter 2017 Financial Results Cash and Equivalents $120.7 million Debt ~$0.3 million YE 2017 Cash (Projected)1 ~$150 million Forecast Quarterly Negative Cash-Flow ~$14-$16 million Shares Outstanding as of October 31,20171 37.1 million 8 1 Includes ~$55 million from an underwritten offering of

  9. Slide 9: Key Takeaways

    NewLink Genetics  The Phase 3 Pivotal trial for patients with advanced melanoma is our top priority and we continue to work toward our goal of completing accrual by the end of 2018.  The AstraZeneca collaboration represents a significant step in our effort to expand the clinical program and differ

  10. Slide 10: Q & A

    10 Q & A

NewLink Genetics — Q3 2017 Earnings Presentation on 6ix